Pharmaceuticals

Amid promising safety signals, Kazia Therapeutics expands its trial for paxalisib in TNBC, a strategic move offering new hope for a hard-to-treat cancer.

A new telehealth platform offers prescription-only CBD, navigating a major regulatory shift that will reshape the entire cannabis industry. Here's what's next.

A landmark Novo Nordisk study finds 2 in 5 heart patients have hidden inflammation, a major risk for heart attack and stroke despite standard treatments.

French biotech TreeFrog Therapeutics isn't just replacing cells; it's implanting pre-wired networks. Their novel 3D microtissue shows faster, more extensive brain repair.

Preliminary data shows IBI363 achieved an 86.4% response rate in advanced lung cancer patients who typically respond poorly to current immunotherapies.

With game-changing Phase III data for iza-bren in breast cancer and a deep pipeline, SystImmune is poised to make a major impact at ASCO 2026.

A revolutionary single-dose, over-the-counter cold sore tablet launches in Europe, promising new convenience for millions and shaking up the self-care market.

Pliant Therapeutics heads to ASCO with data on a novel drug designed to reawaken the immune system's attack on advanced, treatment-resistant tumors.

Teva's new once-monthly olanzapine injection could revolutionize schizophrenia care in Europe, offering hope for better treatment adherence and patient outcomes.

With regulations easing and patient demand soaring, Europe's medical cannabis market is exploding. Canadian firms are racing to stake their claim.

A new guide from QAD | Redzone challenges manufacturers to ditch AI hype and adopt a disciplined, CFO-led approach focused on measurable financial outcomes.

A potential first-in-class antibody-drug conjugate for colorectal cancer begins a pivotal trial, aiming to help patients who have run out of options.

By hiring a third former FDA oncology leader, Precision for Medicine creates an unparalleled regulatory brain trust to speed up cancer drug approvals.

A powerful new combination therapy from Junshi Biosciences and RemeGen gains approval in China, offering unprecedented hope for urothelial carcinoma patients.

With final court approval, Crescita Therapeutics will be delisted from the TSX as global platform ClinActiv snaps up its dermatology assets.

A landmark advocacy effort secures official recognition for clinical research professionals, shining a light on a workforce facing critical shortages and burnout.

With its latest purchase, Harbor IT expands into the Southeast, targeting life sciences and manufacturing with a highly specialized service model.

Dr. Craig Tendler's move to Predicta Biosciences signals a major shift, blending pharma expertise with biotech innovation to revolutionize cancer care.

F1 star Sergio Pérez and Mexican lab Biofarma launch a new supplement line, betting on celebrity power, scientific claims, and a new CSR commitment.

New data shows automated systems are slashing drug approval times and saving patients millions, offering a glimpse into a future with fewer healthcare hurdles.